How this company measures up on the fundamentals that matter
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Trading at $438, 69% above fair value of $259. Strong competitive moat. 36% profit margins. Passes all ethical screens. Ranks better than 62% of screened stocks.
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Trading characteristics and market positioning
Balance sheet strength and cash generation — the foundation of long-term value
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-15 | BUNNAGE MARK E. | Officer | 33 | $14,964 | |
| 2026-05-15 | BOZIC CARMEN | Officer | 1,354 | $613,971 | |
| 2026-05-12 | BOZIC CARMEN | Officer | 6,988 | $3,144,600 | |
| 2026-05-04 | BHATIA SANGEETA N | Director | 318 | $134,746 | |
| 2026-05-01 | THORNBERRY NANCY A. | Director | 472 | — | |
| 2026-05-01 | BHATIA SANGEETA N | Director | 943 | — | |
| 2026-05-01 | MCKENZIE DIANA L | Director | 943 | — | |
| 2026-05-01 | SCHNEIDER JENNIFER J | Director | 472 | — | |
| 2026-05-01 | GARBER ALAN M | Director | 472 | — | |
| 2026-05-01 | LIU JOY | Officer | 1,104 | $469,222 |
Congressional trading disclosures involving this instrument
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-04-13 | Ro Khanna | Democrat | Purchase | 1K–15K |
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15